Adams Street Partners LLC maintained its stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,687,381 shares of the company’s stock at the end of the second quarter. Corvus Pharmaceuticals comprises about 7.6% of Adams Street Partners LLC’s holdings, making the stock its 3rd largest position. Adams Street Partners LLC owned 0.13% of Corvus Pharmaceuticals worth $32,517,000 as of its most recent filing with the SEC.

A number of other hedge funds have also added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. acquired a new stake in Corvus Pharmaceuticals during the second quarter valued at approximately $212,000. Russell Investments Group Ltd. increased its stake in Corvus Pharmaceuticals by 29.3% in the second quarter. Russell Investments Group Ltd. now owns 9,286 shares of the company’s stock valued at $112,000 after buying an additional 2,105 shares during the period. Point72 Asset Management L.P. acquired a new stake in Corvus Pharmaceuticals during the first quarter valued at approximately $8,480,000. Endurant Capital Management LP acquired a new stake in Corvus Pharmaceuticals during the first quarter valued at approximately $282,000. Finally, Renaissance Technologies LLC acquired a new stake in Corvus Pharmaceuticals during the first quarter valued at approximately $1,201,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ CRVS) opened at 11.84 on Tuesday. The stock’s market cap is $247.86 million. The company has a 50-day moving average of $12.16 and a 200 day moving average of $12.81. Corvus Pharmaceuticals, Inc. has a 52-week low of $8.27 and a 52-week high of $22.14.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.76) by $0.03. Equities research analysts forecast that Corvus Pharmaceuticals, Inc. will post ($3.18) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Adams Street Partners LLC Has $32,517,000 Position in Corvus Pharmaceuticals, Inc. (CRVS)” was first posted by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/adams-street-partners-llc-has-32517000-position-in-corvus-pharmaceuticals-inc-crvs/1490129.html.

Several analysts recently commented on the stock. Wedbush reiterated an “outperform” rating and issued a $26.00 price target on shares of Corvus Pharmaceuticals in a research report on Tuesday, August 8th. Zacks Investment Research upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Monday, July 17th. Credit Suisse Group reduced their price target on shares of Corvus Pharmaceuticals from $26.00 to $17.00 and set an “outperform” rating for the company in a research report on Tuesday, July 4th. Finally, Cowen and Company reiterated an “outperform” rating on shares of Corvus Pharmaceuticals in a research report on Tuesday, July 4th. Five equities research analysts have rated the stock with a buy rating, Corvus Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $20.50.

In other news, major shareholder Holdings A/S Novo acquired 20,000 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Friday, June 23rd. The shares were purchased at an average cost of $10.95 per share, for a total transaction of $219,000.00. Following the completion of the purchase, the insider now directly owns 3,244,046 shares of the company’s stock, valued at approximately $35,522,303.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Richard A. Md Miller acquired 25,000 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Tuesday, June 13th. The shares were purchased at an average price of $9.88 per share, for a total transaction of $247,000.00. The disclosure for this purchase can be found here.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Want to see what other hedge funds are holding CRVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS).

Institutional Ownership by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.